14 Aug 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/08/14/3133933/32445/en/Minerva-Neurosciences-Provides-Business-Updates-and-Second-Quarter-Financial-Results.html
28 Feb 2024
// FIERCE BIOTECH
https://www.fiercebiotech.com/biotech/minerva-again-tangled-web-rejection-after-fda-nixes-schizophrenia-drug-2nd-time
10 May 2023
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2023/05/10/2665474/32445/en/Minerva-Neurosciences-Announces-Update-on-its-New-Drug-Application-NDA-for-Roluperidone-for-the-Treatment-of-Negative-Symptoms-in-Schizophrenia.html
01 May 2023
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2023/05/01/2658173/32445/en/Minerva-Neurosciences-Announces-the-NDA-Filing-for-Roluperidone-for-the-Treatment-of-Negative-Symptoms-in-Schizophrenia.html
17 Oct 2022
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2022/10/17/2535492/32445/en/Minerva-Neurosciences-Receives-Refusal-to-File-Letter-from-FDA-for-its-New-Drug-Application-for-Roluperidone-for-the-Treatment-of-Negative-Symptoms-in-Schizophrenia.html
22 Aug 2022
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2022/08/22/2502130/32445/en/Minerva-Neurosciences-Submits-New-Drug-Application-to-FDA-for-Roluperidone-for-the-Treatment-of-Negative-Symptoms-in-Patients-with-Schizophrenia.html